REMARKS

Claims 55-57, 61, 72-74 and 76-81 have been canceled and new claims 82-107 submitted.

Claims 40, 71 and 75 have been amended to require the infectious agent be selected from a specific group of feline viruses. Support for such agents can be found in the specification, for example, on page 12, lines 14-19.

Claims 63-68 have been amended to remove molecules and sequences not relating to feline calicivirus, feline herpesvirus, feline parvovirus or feline leukemia virus.

Claim 70 has been amended to specify the biological specimen is contacted with antigens from several, specific infectious agents. Similarly new claims 98, 106 and 107 state the biological specimen is contacted with antigens from several, specific infectious agents. Support for these claims can be found in the original claims (e.g., claim 23) and in the specification, for example, on page 38, lines 3-4 and on page 40, lines 12-14.

New claims 82-85, 92, 95 and 102 specify the antigen used in the claimed method be at least 85% identical to specific SEQ ID NO's. Support for these claims can be found in the specification, for example, on page 14, lines 16-21, through page 15, lines 1-2.

New claims 86-89, 95 and 104 specify the antigen used in the claimed method be encoded by a nucleic acid molecule at least 85% identical to specific SEQ ID NO's. Support for these claims can be found in the specification, for example, on page 18, lines 5-13.

New claims 92 and 101 specify the antigen used in the claimed method be a particular protein. Support for these claims can be found in the specification, for example, on page 12, lines 9-21, through page 13, lines 1- 6.

Accordingly, Applicants submit no new matter has been entered into the application.

I. Restriction Requirement

Applicants have elected to prosecute Group I for further prosecution. Group I, drawn to a method to determine the immune status of an animal, includes claims 40-75. Proteins of Group I claims include SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32. Nucleic acid molecules encoding proteins of Group I claims include SEQ ID NO:1,

SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31.

II. Sequence Election

The Examiner has stated that each SEQ ID NO is a unique and separately patentable sequence and therefore, Applicants are required to elect a single SEQ ID NO for prosecution. Applicants have provisionally elected SEQ ID NO:22, with traverse for the following reasons.

The Examiner has stated that inventions (e.g., SEQ ID NO's) are unrelated if it can be shown that they are not disclosed as capable of being used together. Applicants note that the SEQ ID NO's listed in the claims have been disclosed as capable of being used together. Applicants are not claiming the individual proteins represented by the specific SEQ ID NO's. Rather, Applicants are claiming a method of determining the immune status of an animal, the method using one or more proteins represented by the listed SEQ ID NO's. In particular, claims 69, 97 and 106, and 70, 98 and 107 are drawn to methods in which the biological specimen is contacted with antigens from three or four, respectively, separate feline viruses. The choice of viruses, and hence antigens, is based on current vaccine methodology which uses a single vaccine containing immunogens from each of these viruses, and which therefore protects against all of these viruses. Thus, one aspect of Applicants invention is a single test which will determine the need to immunize an animal against infection by any of the viruses to which the currently used multi-immunogen vaccine provides protection. Applicants therefore contend this aspect of the instant invention shows how the separate proteins represented by the disclosed SEQ ID NO's can be used together in a single invention, in a meaningful way.

Furthermore, while the claims do list several SEQ ID NO's, Applicants note that several of the SEQ ID NO's completely overlap with other SEQ ID NO's. For example, SEQ ID NO;4 is a truncated version of SEQ ID NO:2. The following chart illustrates the relationships between the SEQ ID NO's disclosed in the claims:

Feline Calicivirus coat protein

SEQ ID NO:1	$nFCVCP_{2013}$	full-length
SEQ ID NO:2	$PFCVCP_{671}$	
SEQ ID NO:3	$nFCVCP_{1641}$	mature
SEQ ID NO:4	$PFCVCP_{547}$	

Feline Parvovirus VP2

SEQ ID NO:5	$nFPVVP2_{1752}$	full-length
SEQ ID NO:6	$PFPVVP2_{584}$	
SEQ ID NO:7	$nFPVVP2C_{729}$	truncated
SEQ ID NO:8	$PFPVVP2C_{243}$	
SEQ ID NO:11	$nFPVpVP2_{1431}$	truncated (start at 5' of #5; end at 3' of #7)
SEQ ID NO:12	$PFPVpVP2_{477}$	

Feline Herpesvirus

gB

SEQ ID NO:13	$nFHVgB_{2829}$	full-length
SEQ ID NO:14	$PFHVgB_{943}$	
SEQ ID NO:15	$nFHVgB_{750}$	truncated
SEQ ID NO:16	$PFHVgB_{250}$	

gC

SEQ ID NO:17	$nFHVgC_{1602}$	full-length
SEQ ID NO:18	$PFHVgC_{534}$	
SEQ ID NO:19	$nFHVgC_{1401}$	truncated
SEQ ID NO:20	$PFHVgC_{467}$	
SEQ ID NO:21	$nFHVgC_{1401(opt)}$	codon-optimized truncated gC
SEQ ID NO:22	$PFHVgC_{467(opt)}$	

gD

SEQ ID NO:23	$nFHVgD_{1122}$	full-length
SEQ ID NO:24	$PFHVgD_{374}$	
SEQ ID NO:25	$nFHVgD_{900}$	truncated
SEQ ID NO:26	$PFHVgD_{300}$	

FeLV p27

SEQ ID NO:27	$nFeLVp27_{789}$	mature
SEQ ID NO:28	$PFeLVp27_{263}$	
SEQ ID NO:29	$nFeLVgp70_{1830}$	full-length
SEQ ID NO:30	$PFeLVgp70_{610}$	
SEQ ID NO:31	$nFeLVp27\text{-}gp70_{1836}$	Pr65-gag/gp70 fusion
SEQ ID NO:32	$PFeLVp27\text{-}gp70_{612}$	

Applicants have included alignments of the protein sequences at the end of this response which clearly illustrate the relationship between overlapping sequences. In view of the overlapping nature of these sequences, Applicants contend that not all of the sequences would need to be searched and therefore no undue burden on the Examiner exists. For example, a search of the prior art for SEQ ID NO:4 would suffice for SEQ ID NO's 1-4. Similarly, a search of the prior art for SEQ ID NO:8 would suffice for SEQ ID NO's 5-12. In fact, Applicants contend the Examiner only need search the prior art for SEQ ID NO's 4, 8, 16, 20, 26, 28 and 30.

In view of the above, Applicants request the Examiner withdraw the sequence election requirement and examine the instantly submitted claim set.

III. Species Election

The Examiner is requiring Applicants to elect one species of recombinant antigen for prosecution stating the species are distinct since their sequences, structures, modes of action, etiologies, etc. are different and therefore each antigen represents a patently distinct subject matter. Applicants have provisionally elected to prosecute a herpesvirus protein, with traverse for the following reasons.

The Examiner is referred to section II of this response. As noted above, one aspect of the present invention is a test capable of determining the immune status of an animal to several different viruses, all of which are protected against by vaccination with a single vaccine. In order to determine the immune status to more than one virus, and consequently to determine the need for the multi-immunogenic vaccine, the claimed method must make use of more than one

antigen (see, for example, claims 69 and 70). Limiting the method to a single antigen makes it useless for determining the need for the commonly used, multi-immunogenic vaccine.

Furthermore, with regard to election of a single species of time, as exemplified by claims 71-74, Applicants note that claims 72-74 have been canceled, obviating this requirement. Therefore, in view of the above, Applicants request the Examiner withdraw the species election requirement and examine the instantly submitted claim set.

CONCLUSION

All of the pending Claims are believed to be in condition for allowance. In the event the Examiner has any questions regarding this Application, the Examiner is invited to contact the undersigned representative at (970) 493-7272, ext. 4174.

Respectfully submitted,

Dated: March 27, 2006

By: 

Richard J. Stern, Ph.D.
Registration No. 50,668
Heska Corporation
3760 Rocky Mountain Avenue
Loveland, Colorado 80538
Telephone: (970) 493-7272
Facsimile: (970) 619-3011

Alignment of SIN2 & SIN4 from DI-9

```
SIN2 mcstcanvlk yydwdphfkl vinpnnflsv gfcsnplmcc ypellpefgt
SIN4 .......... .......... .......... .......... ..........

SIN2 vwdcdrsple iylesilgdd ewastfdavd pvvppmhwga agkifqphpg
SIN4 .......... .......... .......... .......... ..........

SIN2 vlmhhligkv aagwdpdlpl irleADDGSI TAPEQGTMVG GVIAEPSAQM
SIN4 .......... .......... ....ADDGSI TAPEQGTMVG GVIAEPSAQM

SIN2 STAADMATGK SVDSEWEAFF SFHTSVNWST SETQGKILFK QSLGPLLNPY
SIN4 STAADMATGK SVDSEWEAFF SFHTSVNWST SETQGKILFK QSLGPLLNPY

SIN2 LEHLAKLYVA WSGSIEVRFS ISGSGVFGGK LAAIVVPPGV DPVQSTSMLQ
SIN4 LEHLAKLYVA WSGSIEVRFS ISGSGVFGGK LAAIVVPPGV DPVQSTSMLQ

SIN2 YPHVLFDARQ VEPVIFCLPD LRSTLYHLMS DTDTTSLVIM VYNDLINPYA
SIN4 YPHVLFDARQ VEPVIFCLPD LRSTLYHLMS DTDTTSLVIM VYNDLINPYA

SIN2 NDANSSGCIV TVETKPGPDF KFHLLKPPGS MLTHGSIPSD LIPKTSSLWI
SIN4 NDANSSGCIV TVETKPGPDF KFHLLKPPGS MLTHGSIPSD LIPKTSSLWI

SIN2 GNRYWSDITD FVIRPFVFQA NRHFDFNQET AGWSTPRFRP ISVTITEQNG
SIN4 GNRYWSDITD FVIRPFVFQA NRHFDFNQET AGWSTPRFRP ISVTITEQNG

SIN2 AKLGIGVATD YIVPGIPDGW PDTTIPGELI PAGDYAITNG TGNDITTATG
SIN4 AKLGIGVATD YIVPGIPDGW PDTTIPGELI PAGDYAITNG TGNDITTATG

SIN2 YDTADIIKNN TNFRGMYICG SLQRAWGDKK ISNTAFITTA TLDGDNNNKI
SIN4 YDTADIIKNN TNFRGMYICG SLQRAWGDKK ISNTAFITTA TLDGDNNNKI

SIN2 NPCNTIDQSK IVVFQDNHVG KKAQTSDDTL ALLGYTGIGE QAIGSDRDRV
SIN4 NPCNTIDQSK IVVFQDNHVG KKAQTSDDTL ALLGYTGIGE QAIGSDRDRV

SIN2 VRISTLPETG ARGGNHPIFY KNSIKLGYVI RSIDVFNSQI LHTSRQLSLN
SIN4 VRISTLPETG ARGGNHPIFY KNSIKLGYVI RSIDVFNSQI LHTSRQLSLN

SIN2 HYLLPPDSFA VYRIIDSNGS WFDIGIDSDG FSFVGVSGFG KLEFPLSASY
SIN4 HYLLPPDSFA VYRIIDSNGS WFDIGIDSDG FSFVGVSGFG KLEFPLSASY

SIN2 MGIQLAKIRL ASNIRSPMTK L
SIN4 MGIQLAKIRL ASNIRSPMTK L
```

Alignment of SIN6, SIN8 and SIN12 from DI-9

```
SIN6  MSDGAVQPDG GQPAVRNERA TGSGNGSGGG GGGGSGGVGI STGTFNNQTE
SIN8  .......... .......... .......... .......... ..........
SIN12 MSDGAVQPDG GQPAVRNERA TGSGNGSGGG GGGGSGGVGI STGTFNNQTE

SIN6  FKFLENGWVE ITANSSRLVH LNMPESENYK RVVVNNMDKT AVKGNMALDD
SIN8  .......... .......... .......... .......... ..........
SIN12 FKFLENGWVE ITANSSRLVH LNMPESENYK RVVVNNMDKT AVKGNMALDD

SIN6  IHVQIVTPWS LVDANAWGVW FNPGDWQLIV NTMSELHLVS FEQEIFNVVL
SIN8  .......... .......... .......... .......... ..........
SIN12 THVQIVTPWS LVDANAWGVW FNPGDWQLIV NTMSELHLVS FEQEIFNVVL

SIN6  KTVSESATQP PTKVYNNDLT ASLMVALDSN NTMPFTPAAM RSETLGFYPW
SIN8  .......... .......... .......... .......... ..........
SIN12 KTVSESATQP PTKVYNNDLT ASLMVALDSN NTMPFTPAAM RSETLGFYPW

SIN6  KPTIPTPWRY YFQWDRTLIP SHTGTSGTPT NVYHGTDPDD VQFYTIENSV
SIN8  .......... .......... .......... ....GTDPDD VQFYTIENSV
SIN12 KPTIPTPWRY YFQWDRTLIP SHTGTSGTPT NIYHGTDPDD VQFYTIENSV

SIN6  PVHLLRTGDE FATGTFFFDC KPCRLTHTWQ TNRALGLPPF LNSLPQSEGA
SIN8  PVHLLRTGDE FATGTFFFDC KPCRLTHTWQ TNRALGLPPF LNSLPQSEGA
SIN12 PVHLLRTGDE FATGTFFFDC KPCRLTHTWQ TNRALGLPPF LNSLPQSEGA

SIN6  TNFGDIGVQQ DKRRGVTQMG NTDYITEATI MRPAEVGYSA PYYSFEASTQ
SIN8  TNFGDIGVQQ DKRRGVTQMG NTDYITEATI MRPAEVGYSA PYYSFEASTQ
SIN12 TNFGDIGVQQ DKRRGVTQMG NTDYITEATI MRPAEVGYSA PYYSFEASTQ

SIN6  GPFKTPIAAG RGGAQTDENQ AADGDPRYAF GRQHGQKTTT TGETPERFTY
SIN8  GPFKTPIAAG RGGAQTDENQ AADGDPRYAF GRQHGQKTTT TGETPERFTY
SIN12 GPFKIPIAAG RGGAQTDENQ AADGDPRYAF GRQHGQKTTT TGETPERFTY

SIN6  IAHQDTGRYP EGDWIQNINF NLPVTNDNVL LPTDPIGGKT GINYTNIFNT
SIN8  IAHQDTGRYP EGDWIQNINF NLPVTNDNVL LPTDPIGGKT GINYTNIFNT
SIN12 IAHQDTGRYP AGDWIQNINF NLPVTNDNVL LPTDPIGGKT GINYTNIFNT

SIN6  YGPLTALNNV PPVYPNGQIW DKEFDTDlkp rlhvnapfvc qnncpgqlfv
SIN8  YGPLTALNNV PPVYPNGQIW DKEFDTD... .......... ..........
SIN12 YGPLTALNNV PPVYPNGQIW DKEFDTD... .......... ..........

SIN6  kvapnltney dpdasanmsr ivtysdfwwk gklvfkaklr ashtwnpiqq
SIN8  .......... .......... .......... .......... ..........
SIN12 .......... .......... .......... .......... ..........

SIN6  msinvdnqfn yvpnnigamk ivyeksqlap rkly
SIN8  .......... .......... .......... ....
SIN12 .......... .......... .......... ....
```

Alignment of SEQ ID NO's 14 & 16 from DI-9

```
SIN14 MSTRGDLGKR RRGSRWQGHS GYFRQRCFFP SLLGIAATGS RHGNGSSGLT
SIN16 MSTRGDLGKR RRGSRWQGHS GYFRQRCFFP SLLGIAATGS RHGNGSSGLT

SIN14 RLARYVSFIW IVLFLVGPRP VEGQSGSTSE QPRRTVATPE VGVHHQNQLQ
SIN16 RLARYVSFIW IVLFLVGPRP VEGQSGSTSE QPRRTVATPE VGVHHQNQLQ

SIN14 IPPICRYEEA LRASQIEANG PSTFYMCPPP SGSTVVRLEP PRACPDYKLG
SIN16 IPPICRYEEA LRASQIEANG PSTFYMCPPP SGSTVVRLEP PRACPDYKLG

SIN14 KNFTEGIAVI FKENIAPYKF KANIYYKNII MTTVWSGSSY AVTTNRYTDR
SIN16 KNFTEGIAVI FKENIAPYKF KANIYYKNII MTTVWSGSSY AVTTNRYTDR

SIN14 VPVKVQEITD LIDRRGMCLS KADYVRNNYQ FTAFDRDEDP RELPLKPPSS
SIN16 VPVKVQEITD LIDRRGMCLS KADYVRNNYQ FTAFDRDEDP RELPLKPPSS

SIN14 tlsrvrgwht netytkivll dfhhsgtsvn civeevdars vypydsfais
SIN16 .......... .......... .......... .......... ..........

SIN14 tgdvihmspf fglrdgahve htsyssdrfq qiegyypidl dtdytgapvs
SIN16 .......... .......... .......... .......... ..........

SIN14 rnfletphvt vawnwtpksg rvctlakwre idemlpmnig syrftaktis
SIN16 .......... .......... .......... .......... ..........

SIN14 atfisntsqf einrirlgdc atkeaaeaid riykskyskt hiqtgtlety
SIN16 .......... .......... .......... .......... ..........

SIN14 larggfliaf rpmisnelak lyinelarsn rtvvdlsall npsgetvqrt
SIN16 .......... .......... .......... .......... ..........

SIN14 rrsvpsnqhh rsrrstiegg ietvnnasll kttssvefam lqfaydyiqa
SIN16 .......... .......... .......... .......... ..........

SIN14 hvnemlsria tawctlqnre hvlwtetlkl npggvvsmal errvsarllg
SIN16 .......... .......... .......... .......... ..........

SIN14 davavtqcvn issghvyiqn smrvtgsstt cysrplvsfr alndseyieg
SIN16 .......... .......... .......... .......... ..........

SIN14 qlgennellv erkliepctv nnkryfkfga dyvyfedyay vrkvplseie
SIN16 .......... .......... .......... .......... ..........

SIN14 lisayvikst lledreflhs sytraeledt gpfdyseiqr rnqlhalkfy
SIN16 .......... .......... .......... .......... ..........
```

```
SIN14 didsivrvdn nlvimrgman ffqglgdvga gfgkvvlgaa savistvsgv
SIN16 .......... .......... .......... .......... ..........

SIN14 ssflnnpfga lavgllilag ivaaflayry isrlranpmk alypvttrnl
SIN16 .......... .......... .......... .......... ..........

SIN14 kqtakspast aggdsdpgvd dfdeeklmqa remikymslv sameqqehka
SIN16 .......... .......... .......... .......... ..........

SIN14 mkknkgpail tshltnmalr rrgpkyqrln nldsgddtet nlv
SIN16 .......... .......... .......... .......... ...
```

Alignment of SIN18, SIN20 and SIN22 from DI-9

```
SIN18 mrryrmgrgi yllyicllyt ylqfgtsstt avSIENSDNS TAEMLSSTSM
SIN20 .......... .......... .......... ..SIENSDNS TAEMLSSTSM
SIN22 m......... .......... .......... ..SIENSDNS TAEMLSSTSM

SIN18 SATTPISQPT SPFTTPTRRS TNIATSSSTT QASQPTSTLT TLTRSSTTIA
SIN20 SATTPISQPT SPFTTPTRRS TNIATSSSTT QASQPTSTLT TLTRSSTTIA
SIN22 SATTPISQPT SPFTTPTRRS TNIATSSSTT QASQPTSTLT TLTRSSTTIA

SIN18 TSPSTTQAAT FIGSSTDSNT TLLKTTKKPK RKKNKNNGAR FKLYCGYKGV
SIN20 TSPSTTQAAT FIGSSTDSNT TLLKTTKKPK RKKNKNNGAR FKLYCGYKGV
SIN22 TSPSTTQAAT FIGSSTDSNT TLLKTTKKPK RKKNKNNGAR FKLdCGYKGV

SIN18 IYRPYFSPLQ LNCTLPTEPH ITNPIDFEIW FKPRTRFGDF LGDKEDFVGN
SIN20 IYRPYFSPLQ LNCTLPTEPH ITNPIDFEIW FKPRTRFGDF LGDKEDFVGN
SIN22 IYRPYFSPLQ LNCTLPTEPH ITNPIDFEIW FKPRTRFGDF LGDKEDFVGN

SIN18 HTRTSILLFS SRNGSVNSMD LGDATLGILQ SRIPDYTLYN IPIQHTEAMS
SIN20 HTRTSILLFS SRNGSVNSMD LGDATLGILQ SRIPDYTLYN IPIQHTEAMS
SIN22 HTRTSILLFS SRNGSVNSMD LGDATLGILQ SRIPDYTLYN IPIQHTEAMS

SIN18 LGIKSVESAT SGVYTWRVYG GDVLNKTVLG QVNVSVVAYH PPSVNLTPRA
SIN20 LGIKSVESAT SGVYTWRVYG GDVLNKTVLG QVNVSVVAYH PPSVNLTPRA
SIN22 LGIKSVESAT SGVYTWRVYG GDGLNKTVLG QVNVSVVAYH PPSVNLTPRA

SIN18 SLFNKTFEAV CAVANYFPPR STKLTWYLDG KPIERQYISD TASVWIDGLI
SIN20 SLFNKTFEAV CAVANYFPPR STKLTWYLDG KPIERQYISD TASVWIDGLI
SIN22 SLFNKTFEAV CAVANYFPPR STKLTWYLDG KPIERQYISD TASVWIDGLI

SIN18 TRSSVLAIPT TETDSEKPDI RCDLEWHESP VSYKRFTKSV APDVYYPPTV
SIN20 TRSSVLAIPT TETDSEKPDI RCDLEWHESP VSYKRFTKSV APDVYYPPTV
SIN22 TRSSVLAIPT TETDSEKPDI RCDLEWHESP VSYKRFTKSV APDVYYPPTV

SIN18 SVTFADTRAI CDVKCVPRDG ISLMWKIGNY HLPKAMSADI LITGPCIERP
SIN20 SVTFADTRAI CDVKCVPRDG ISLMWKIGNY HLPKAMSADI LITGPCIERP
SIN22 SVTFADTRAI CDVKCVPRDG ISLMWKIGNY HLPKAMSADI LITGPCIERP

SIN18 GLVNIQSMCD ISETDGPVSY TCQTIGYPPI LPGFYDTQVY DASPEIVSEs
SIN20 GLVNIQSMCD ISETDGPVSY TCQTIGYPPI LPGFYDTQVY DASPEIVSE.
SIN22 GLVNIQSMCD ISETDGPVSY TCQTIGYPPI LPGFYDTQVY DASPEIVS..

SIN18 mlvsvvavil gavlitvfif italclyysh prrl
SIN20 .......... .......... .......... ....
SIN22 .......... .......... .......... ....
```

Alignment of SEQ ID NO's 24 & 26 from DI-9

```
SIN24 mmtrlhfwwc gifavlkylv ctssltttPK TTTVYVKGFN IPPLRYNYTQ
SIN26 .......... .......... ........PK TTTVYVKGFN IPPLRYNYTQ

SIN24 ARIVPKIPQA MDPKITAEVR YVTSMDSCGM VALISEPDID ATIRTIQLSQ
SIN26 ARIVPKIPQA MDPKITAEVR YVTSMDSCGM VALISEPDID ATIRTIQLSQ

SIN24 KKTYNATISW FKVTQGCEYP MFLMDMRLCD PKREFGICAL RSPSYWLEPL
SIN26 KKTYNATISW FKVTQGCEYP MFLMDMRLCD PKREFGICAL RSPSYWLEPL

SIN24 TKYMFLTDDE LGLIMMAPAQ FNQGQYRRVI TIDGSMFYTD FMVQLSPTPC
SIN26 TKYMFLTDDE LGLIMMAPAQ FNQGQYRRVI TIDGSMFYTD FMVQLSPTPC

SIN24 WFAKPDRYEE ILHEWCRNVK TIGLDGARDY HYYWVPYNPQ PHHKAVLLYW
SIN26 WFAKPDRYEE ILHEWCRNVK TIGLDGARDY HYYWVPYNPQ PHHKAVLLYW

SIN24 YRTHGREPPV RFQEAIRYDR PAIPSGSEDS KRSNDSRGES SGPNWIDIEN
SIN26 YRTHGREPPV RFQEAIRYDR PAIPSGSEDS KRSNDSRGES SGPNWIDIEN

SIN24 YTPKNNVPII ISDDDVPTAP PKGMNNQSvv ipaivlscli ialilgviyy
SIN26 YTPKNNVPII ISDDDVPTAP PKGMNNQS.. .......... ..........

SIN24 ilrvkrsrst ayqqlpiiht thhp
SIN26 .......... .......... ....
```